The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease

Journal of the American Geriatrics Society

Volumn 58, Issue 5, 2010, Pages 1000-1001

  Hanyu, Haruo ^a   Sato, Tomohiko ^a   Sakurai, Hirofumi ^a   Iwamoto, Toshihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AGED; ALZHEIMER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LETTER; MALE; MINI MENTAL STATE EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGONISTS; BLOOD; PHYSIOLOGY;

AGED; ALZHEIMER DISEASE; COGNITION; FEMALE; HUMANS; MALE; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952130974     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02841.x     Document Type: Letter

References (8)

1. Watson GS, Cholerton BA, Reger MA et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone. A preliminary study. Am J Geriatr Psychiatry 2005 13:950 958.
2. Risner ME, Saunders AM, Altman JFB et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenom J 2006 6:246 254. (Pubitemid 44137951)
3. Hanyu H, Sato T, Kiuchi A et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc 2009 57:177 179.
4. Heneka MT, Sastre M, Dumitrescu-Ozimek L et al. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 2005 128:1442 1453. (Pubitemid 40826196)
5. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34:939 944. (Pubitemid 14076461)
6. Sastre M, Dewachter I, Rossner S et al. Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPRAγ. Proc Natl Acad Sci USA 2006 103:443 448. (Pubitemid 43122420)
7. Holmes C, Cunningham C, Zotova E et al. Systemic inflammation and disease progression in Alzheimer's disease. Neurology 2009 73:768 774.
8. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature 2006 440:11054 11059.